Curated News
By: NewsRamp Editorial Staff
September 14, 2026
Quantum BioPharma's Lucid-MS Wins FDA Nod for Phase 2 MS Trial
TLDR
- Quantum BioPharma secured FDA IND clearance for Lucid-MS, enabling a Phase 2 multiple sclerosis trial that could yield a first-in-class treatment.
- The FDA cleared Quantum BioPharma's 15,000-page IND for Lucid-MS, allowing a randomized, double-blind, placebo-controlled Phase 2 trial in multiple sclerosis.
- Quantum BioPharma's Lucid-MS may prevent and reverse myelin damage, offering new hope to people living with multiple sclerosis.
- Quantum BioPharma's Lucid-MS, a patented new chemical, cleared a major FDA hurdle and now advances to Phase 2 trials for multiple sclerosis.
Impact - Why it Matters
This news matters because it represents a potential breakthrough in the treatment of multiple sclerosis, a chronic and often debilitating disease affecting millions worldwide. Current therapies primarily manage symptoms and slow progression but do not reverse myelin damage. Lucid-MS, with its novel mechanism to prevent and reverse myelin degradation, could offer a disease-modifying approach that addresses the root cause. The FDA's clearance of the IND allows Quantum BioPharma to initiate a Phase 2 trial, bringing this promising therapy one step closer to patients. For investors, this milestone validates the company's scientific approach and could significantly enhance its value, especially given the high unmet need in MS. Moreover, the successful advancement of Lucid-MS may open doors for further innovation in neurodegenerative disorders, positioning Quantum BioPharma as a key player in the biotech space.
Summary
Quantum BioPharma (NASDAQ: QNTM) has achieved a significant regulatory milestone with the FDA clearance of its Investigational New Drug (IND) application for Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. According to the company, the roughly 15,000-page IND submission included a comprehensive package of pharmacology, toxicology, and manufacturing data, enabling Quantum to advance directly into a randomized, double-blind, placebo-controlled Phase 2 trial in people with MS. This clearance marks a critical step forward for the micro-cap biotech, which is dedicated to developing innovative treatments for challenging neurodegenerative and metabolic disorders. The news was highlighted in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach.”
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. Beyond its MS program, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The latest updates on QNTM are available in the company’s newsroom at https://nnw.fm/QNTM. The announcement was distributed through NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Wins FDA Nod for Phase 2 MS Trial
